Month: September 2020

139-07-1, N-Benzyl-N,N-dimethyldodecan-1-aminium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Solution A: A 5 mL volume of 160 mM sodium molybdate dihydrate is diluted with 5 mL of water and the acidity of the solution is adjusted to pH 2 with 0.1 M sulfuric acid. About 1 mL of 36% hydrogen peroxide is added and the resulting solution is diluted to 20 mL with water. Solution B: Oxalic acid dihydrate (0.106 grams) is added into 2.5 ml of an aqueous solution of alkyldimethylbenzylammonium chloride (0.604 grams) and the resulting solution is diluted to 5 mL with water. In an ice-cold condition with vigorous stirring, solution A is added dropwise into solution B and the pH of the resulting solution is maintained at pH 2 by adding sulfuric acid. After 5 minutes, the formation of the precipitate is observed. The reaction mixture is centrifuged and the precipitate is washed 2-3 times with water and dried under vacuum (yield of compound 3 was 85%).

139-07-1, As the paragraph descriping shows that 139-07-1 is playing an increasingly important role.

Reference£º
Patent; INDIAN INSTITUTE OF TECHNOLOGY MADRAS; CHAND, Dillip Kumar; CHAKRAVARTHY, Rajan Deepan; (16 pag.)US2016/251388; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

EXAMPLE 285 2,3-Dihydro-2-[1-[3-phenyl-3-(4-propylphenyl)propyl]-4-piperidinyl]-1H-isoindol-1-one, monohydrochloride STR169 To a suspension of magnesium turnings (1.0 g, 41.2 mmol) in THF (8.2 mL) was added a solution of 1-bromo-4-propylbenzene (Aldrich) (1.64 g, 8.20 mmol) in THF (8.2 mL). The reaction was refluxed for 1.5 h, then cooled to RT. The Grignard solution was cannulated then titrated against 1.0M isopropanol in toluene using 2,2-biquinoline as an indicator to give title compound (0.35M, 70%) as a black solution. STR170 To a solution of Example 284 compound (500 mg, 1.37 mmol) in THF (8 mL) was added dropwise at 0 C. a solution of Part A compound (4.3 mL, 1.51 mmol). The reaction was stirred at 0 C. for 3 h then warmed to RT for 3 h. The reaction was quenched with saturated ammonium chloride solution (3 mL). Ethyl ether (200 mL) was added and the organic was washed with water (2*50 mL), brine (2*50 mL) and dried over MgSO4. Evaporation gave title compound (400 mg, 63%) as a crude oil., 119-91-5

The synthetic route of 119-91-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Bristol-Myers Squibb Company; US5739135; (1998); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

787-70-2, [1,1′-Biphenyl]-4,4′-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,787-70-2

A mixture of H2BPDC (0.097g, 0.4mmol), Melamine (0.050g, 0.4mmol), DMF (4mL), ethanol (4mL) and H2O (4mL) was sealed into a 20mL Teflon-lined stainless-steel reactor and heated at 105C for 3days under autogenous pressure, and then followed by slowly cooling to room temperature at a rate of 1.7C¡¤h-1. The obtained flavescens cuboid-like crystals of 1 were collected (yield: 80 % based on Melamine) after washing with ethanol and drying in air. Elemental analysis: calcd. (%) for C20H30N12O8: C: 42.40, H: 5.34, N: 29.67, O: 22.59; found: C: 42.11, H: 5.81, N: 29.32, O: 22.76. FT-IR (KBr, 4000-500cm-1)=3380(w), 2667(w), 1890(m), 1686(vs), 1632(s), 1509(vs), 1390(m), 1205(m), 1009(w), 1004(m), 850(s), 760(s), 700(s) cm-1.

The synthetic route of 787-70-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Liu, Ruichao; Liu, Jie; Yan, Xiangzhen; Yuan, Chunxue; Polyhedron; vol. 157; (2019); p. 1 – 5;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

2304-30-5, Tetrabutylphosphonium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,2304-30-5

EXAMPLE 2 2-Benzylthio-5-chlorophenylisonitrile A reaction flask was charged under a nitrogen atmosphere with 6 g (0.03 mole) of 2-mercapto-5-chloroaniline hydrochloride, 4 g (0.03 mole) of benzyl chloride, 5 ml of 50% aqueous sodium hydroxide, and 250 mg of tetra-n-butylphosphonium chloride. The mixture was heated to reflux for two hours, and 3 ml each of benzene and water were added. The organic phase was then washed with a 10% caustic solution and evaporated to yield 8.1 g of a black oil, confirmed by mass spectroscopy to be 2-benzylthio-5-chloroaniline. A reaction flask was then charged with 6 g (0.02 mole) of this product, 5 ml of chloroform, 10 ml of methylene chloride, 10 ml of 50% aqueous sodium hydroxide solution, and 100 mg of benzyltriethylammonium chloride. The procedure of Example 1 was then followed, producing 6 g of a black oil, which was passed through an alumina chromatography column with hexane, followed by a hexane-benzene mixture.

2304-30-5 Tetrabutylphosphonium chloride 75311, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Stauffer Chemical Company; US4380468; (1983); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.39069-02-8,2,9-Dibromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

Reference Example 1(2,9-bis(6-((Methoxymethyloxy)methyl)pyridine-2-yl)-1,10-phenanthroline) (20)[0109] [Chem. 15] [0110] Under a stream of argon, 2,9-dibromo-1,10-phenanthroline (compound (10); 3.25 g; 9.6 mmol) was dissolved in anhydrous dimethylformamide (45 mL). To the reaction mixture, 2-methoxymethyloxymethylpyridine-6-yl tributyltin (compound (12); 17 g; 9.6 mmol) and triphenylphosphine palladium dichloride (3.83 g; 4.8 mmol) were added, followed by stirring at 70 oC for 22 hours. The reaction mixture was cooled to room temperature, and Rochelle salt was added thereto. Subsequently, the reaction mixture was poured into saline, and ethyl acetate was added thereto. Insoluble matters were filtered out, and the filtrate was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, and then evaporated under reduced pressure to give oil matters. Under a stream of argon, the resulting oil matters were dissolved in anhydrous dimethylformamide (45 mL), and compound (12) (17 g; 9.6 mmol) and triphenylphosphine palladium dichloride (2.72 g; 3.38 mmol) were added thereto, followed by stirring at 70 oC for 20 hours. The reaction mixture was cooled to room temperature, and Rochelle salt was added thereto. Subsequently, the reaction mixture was poured into saline, and ethyl acetate was added thereto. Insoluble matters were filtered out, and the filtrate was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, and then evaporated under reduced pressure to give a residue. The resulting residue was separated and purified by silica gel column chromatography (SiO2, 200 g; developing solvent: chloroform/methanol = 30/1 to 20/1 to 10/1), to give 1.1 g (yield: 23.7%) of the title compound (20).[0111] 1H NMR (DMSO-d6)d: 3.38 (s, 3 H), 4.80-4.83 (m, 8 H), 7.64 (d, J = 8 Hz, 2 H), 8.07-8.20 (m, 4 H), 8.65-8.84 (m, 4 H), 8.92 (d, J = 7 Hz, 1 H)HPLC mobile phase: 40-95% acetonitrile – water (0.1% trifluoroacetic acid)Peak retention time: 5.7 minutesESIMS (positive) m/z 483.1, (M+H) (F.W = 482.53 for C28H26N4O4), 39069-02-8

As the paragraph descriping shows that 39069-02-8 is playing an increasingly important role.

Reference£º
Patent; B.R.A.H.M.S GmbH; HOSHINO, Mikio; YANO, Toshisada; YAMANAKA, Yasukazu; WO2012/124310; (2012); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

99970-84-0, [2,2′-Bipyridine]-4,4′-dicarbaldehyde is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a flame-dried round bottle flask with a magnetic stirring bar were addedbipyridine aldehyde (0.001 mmol) 2 and (DABCO) as catalyst (10 mol%)) in methanol(4mL), followed by the addition of activated alkenes 4. The resulting mixture was stirred atroom temperature for 12 hours, after completion of the reaction (Monitored by TLC),solvents were removed in vacuo and the residue was purified on neutral alumina using 70%ethyl acetate in petroleum ether to afford the corresponding novel Morita-Baylis-Hillmanadduct of bipyridine 5 in very good yield., 99970-84-0

The synthetic route of 99970-84-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Gouthaman, Siddan; Periyaraja, Somasundharam; Shanmugam, Ponnusamy; Tetrahedron Letters; vol. 56; 43; (2015); p. 5920 – 5923;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

COMPOUND 28; 5,15-bis-[3-(3-Trimethylammmonio-propylox)0-ph.enyl]-10-undecyl- porphyrin dichloride; To a solution of Compound 27 (50 mg, 0.08 mmol) in DMF (20 mL) under an argon atmosphere K2CO3 (100 mg, 0.72 mmol) and (3- bromopiOpyl)-trimethylammonium bromide (300 mg, 1.2 mmol) are added and the mixture is stirred at 500C for 18 h. After removal of solvent under high vacuum the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (500 mL) it is eluted with acetic acid:methanol:water (3:2:1, v:v). After drying of appropriate combined fractions under high vacuum the residue is dissolved in methanol and purified by column chromatography on Sephadex LH-20 eluting with n-butanol: acetic acid: water (5: 1:4, by vol., upper phase). After evaporation of solvent the residue obtained from the first fraction eluted is dissolved in methanol and passed through a short column of anion exchange resin (Amberlite IRA 400. chloride form) to give, after evaporation of solvent, the pure product.1H-NMR: deltaH (300Mz, CD3OD): 0.85 (t, 3Z 7.5 Hz, 3 H), 1.20-1.40 (m, 12 H), 1.50 (m, 2 H), 1.80 (m, 2 H), 2.40 (bs, 4 H), 2.55 (m, 2 H), 3.20 (bs, 18 H), 3.65 (bs, 4 H), 4.35 (bs, 4 H), 5.10 (m, 2 H), 7.50-7.55, 7.70-7.85 (2 x m, 8 H), 8.95-9.00, 9.25-9.24, 9.50-9.70 (3 x bs, 8 H), 10.15 (bs5 IH).

3779-42-8, 3779-42-8 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide 151145, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

137076-54-1, To a solution of product 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (572.7 mg, 1 mmol) in dry DMF (15 ml), amino-maleinnide 137 (483.3 mg, 1 mmol) was added with HATU (272 mg, 1 .4 mmol) and DIPEA (360 mul, 1.84 mmol). The mixture was stirred overnight at room temperature. After removing the solvent under the vacuum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give compound tri-tert-butyl 2,2′,2″-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (396 mg, 57 %). Rf : 0.3 (CH2Cl2/MeOH, 90:10). 1H NMR (300MHz, CDCl3) delta 8.30 (b, 1 H, NH), 6.86 (s,2H, H6′), 3.78-3.54 (br, 4H, H3′, H4′), 3.54 (br, 4H, H13, H1′), 3.48 (br, 4H, H8), 3.09-2.99 (m, 8H, H2, H3), 2.97-2.86 (m, 8H, H5, H6), 1 .46 (s, 18H, H12), 1 .45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 171 .6 (C2′), 171 .0 (C5′), 170.4 (C9, C14), 134.2 (C6′), 81 .5 (C16), 81 .3 (C11), 57.8 (C1′), 55.7-55.2 (C8, C13), 54.1 – 51 .5 (C2, C3), 51 .0-48.9 (C5, C6), 38.0 (C4′), 32.7 (C3′), 27.8 (C17), 27.6 (C12). MS (ESI) : m/z 695 [M + H]+.

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); FLORENT, Jean-Claude; AIT SARKOUH, Rafik; JOHANNES, Ludger; SCHMIDT, Frederic; OBERLEITNER, Birgit; DRANSART, Estelle; SEMETEY, Vincent; WO2014/86942; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(7) To a mixture of compound (K6) (84.3 mg), tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (60.7 mg), DMF (1 mL), and DIEA (50 muL), HBTU (40.2 mg) was added, and the resulting mixture was stirred at room temperature for 30 minutes. Water (1 mL), methanol (0.5 mL), and formic acid (200 muL) were added thereto, and the mixture was purified by preparative HPLC to obtain compound (K7) (61.9 mg). LC/MS (ACQUITY) rt (min): 1.12 MS (ESI, m/z): 677.4 [M+2H]2+, 1351.3 [M-H]-, 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1119-97-7, MitMAB is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A 100mL round-bottom flask was equipped with a magnetic stir bar and a reflux condenser. To xylene (10.0mL), tetradecyltrimethylammonium bromide (1.1mmol) and a heterocyclic compound (1.0mmol) were added, followed bya solution of NaOH 50% (5.0 mL). The mixture was stirred at reflux temperature for 2-18 h. After completion of thereaction, the mixture was air-jet cooled to 25 C and TLC indicated the disappearance of the starting material. The reaction mix was treated with AcOEt (4 ¡Á 20 mL), and the organic phase separated and removed under reduced pressure. The residue was purified to analytical purity by column chromatography., 1119-97-7

As the paragraph descriping shows that 1119-97-7 is playing an increasingly important role.

Reference£º
Article; Gonzalez-Gonzalez, Carlos A.; Vega, Juan Javier Mejia; Monroy, Ricardo Garcia; Gonzalez-Calderon, Davir; Corona-Becerril, David; Fuentes-Benites, Aydee; Mascarua, Joaquin Tamariz; Gonzalez-Romero, Carlos; Journal of Chemistry; vol. 2017; (2017);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI